Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients.
Materials and Methods
We retrospectively investigated 142 pediatric patients younger than 3 years presenting at the Gynaecologic and Pediatric Hospital (Linz, Austria) between January 2003 and January 2004. Infants younger than 1 month were excluded because high concentrations of natriuretic peptides immediately after delivery with a subsequent rapid decrease have been reported (21). The study is consistent with the Declaration of Helsinki. Peripheral venous blood was drawn for routine blood analysis. Serum was stored at -20 [degrees]C for occasional reassessment of routine tests, and NT-proBNP concentrations were additionally batch measured within 7 months. The population comprised pediatric patients with cardiac diseases [median (minimum-maximum) age, 75 (33-1042) days; n = 23] as assessed by echocardiography, and infants with no history of heart disease and no signs of heart disease on physical examination [median (minimum-maximum) age, 486 (33-1070) days; n = 119]. Patients without complete data were not included. The infants with cardiac diseases were as follows: 2 with valvular heart disease (tricuspid valve stenosis, n = 1; pulmonary valve stenosis, n = 1); 17 with congenital heart diseases (complex congenital heart diseases, n = 11; atrial septal defects, n = 3, ventricular septal defects, n = 3); 2 with dilated cardiomyopathy; 1 with acute pericarditis; and 1 with cardiac shock with papillary muscle rupture. Infants with cardiac diseases mostly presented with combined defects, with a total of 16 infants suffering from right heart volume overload, 9 suffering from left heart volume overload, 8 suffering from right ventricular pressure load, 1 suffering from left ventricular pressure load, 9 suffering from clinical heart failure, and 6 presenting with cyanosis. All infants with cardiac diseases were classified according to the New York University Pediatric Heart Failure Index (NYU PHFI), which is a heart failure score based on signs and symptoms, physiology, and current medications. Healthy children have low NYU PHFI scores ([less than or equal to] 2), whereas children with left-to-right shunt lesions have scores of -11 (24).
Children with noncardiac diseases (controls) presented with kidney diseases, including tumors (n = 7); lung diseases (n = 15); central nervous system disorders (n = 9); infectious diseases (n = 42); liver disorders (n = 4); epilepsy (n = 9); a connective tissue tumor (n = 1); malformation (n = 6); and minor diseases (n = 26) such as gall or kidney stones, reflux, vomiting, noninfectious diarrhea, sleep apnea, and hypertrophy of tonsils.
NT-proBNP(1-76) was measured by a sandwich electrochemiluminescence immunoassay (Elecsys 1010; Roche Diagnostics) with polyclonal antibodies specific against the epitopes NT-proBNP(1-21) and NT-proBNP(39-50) as described previously (25, 26). The interassay CV was 1.1% at a NT-proBNP concentration of 170 ng/L (n = 20) and 1.4% at a NT-proBNP concentration of 5080 ng/L (n = 20); the interassay CVs at the same NT-proBNP concentrations were 6.0% (n = 20) and 3.6% (n = 20), respectively.
ROC curve analysis (27) was carried out to investigate the diagnostic performance of NT-proBNP for identifying infants with heart diseases. For this reason, the whole study population was used. Because of differences in age, we performed a subanalysis in which children with cardiac diseases were randomly paired with age- and sex-matched children with noncardiac diseases. The Mann-Whitney U-test was used for group comparisons. Linear regression analysis was performed in log(10)transformed NT-proBNP values as well. Data are given as the median (25th-75th percentiles). P <0.05 was considered to indicate statistical significance.
There was no significant difference in sex distribution between the 23 infants with cardiac diseases and the 119 infants with other diseases. However, there was a significant difference in age (P = 0.002), which may be explained by the fact that the group with cardiac diseases was smaller and that these infants mostly had severe cardiac diseases, which manifest early in life. Creatinine concentrations were below the upper reference limit in all infants. Median NT-proBNP concentrations were significantly (P <0.0001) increased in infants with cardiac diseases [3681 (1045-13 557) ng/L] compared with infants with noncardiac diseases [241 (116-542) ng/L; Table 1]. When infants with noncardiac diseases were further divided into subgroups of kidney, lung, central nervous system, and other diseases, NT-proBNP concentrations were significantly higher in the infants with cardiac disease than in the infants of each subgroup (Table 1). The ROC curve analysis (Fig. 1) showed good performance for NT-proBNP to differentiate between infants with cardiac diseases and infants with other diseases, with a mean [95% confidence interval (CI)] area under curve (AUC) of 0.87 (0.76-0.94). At the optimal cutoff of 2000 ng/L, which gave the highest diagnostic accuracy based on the ROC curve analysis, the mean (95% CI) sensitivity was 74% (51%-89%), the specificity was 95% (89%-98%), the positive predictive value was 74% (51%-89%), the negative predictive value was 95% (75%-100%), and the accuracy was 92% (85%-95%). Additionally, infants with cardiac diseases and clinical signs of heart failure had significantly (P = 0.020) higher NT-proBNP concentrations [median (25th-75th percentiles), 8307 (3606-26 043) ng/L] than infants with cardiac diseases but without symptoms of heart failure [2850 (462-6554) ng/L]. The median (25th-75th percentiles) NYU PHFI score was 8 (3-16) in infants with cardiac diseases and correlated significantly with NT-proBNP concentrations (r = 0.662; P = 0.001; n = 23).
[FIGURE 1 OMITTED]
We also performed a linear regression analysis in the whole study population (n = 142), which revealed a significant influence of the presence of cardiac disease (P <0.0001) and of age (P <0.0001) on log(10)-transformed NT-proBNP concentrations. There was no significant influence of sex (P = 0.318).
Because of the significant difference in age in this population, we performed a subanalysis using random age- and sex-matched controls for each infant with cardiac disease, which revealed results similar to those obtained with the whole study population. Two male patients could not be exactly matched with controls and had to be excluded. The final study population of this subanalysis comprised 21 matched pediatric patients with a mean age difference of -2.9 days (P = 0.772). NT-proBNP concentrations were still significantly higher (P <0.0001) in infants with cardiac disease [median (25th-75th percentiles), 3530 (838-8370) ng/L] than in infants with other diseases [444 (205-1493) ng/L]. The mean [AUC.sub.RCC] (95% CI) was 0.84 (0.68-0.93). At the optimal cutoff of 2000 ng/L, which had the highest diagnostic accuracy based on the ROC curve analysis, the mean (95% CI) sensitivity was 71% (48%-88%), the specificity was 86% (63%-96%), the positive predictive value was 83% (58%-96%), the negative predictive value was 75% (49%-91%), and the accuracy was 79% (63%-89%).
The novel finding of this study is that in a heterogeneous group of young pediatric patients who came to the hospital because of various signs and symptoms, NT-proBNP was a suitable marker to rule out cardiac disease. Because there are controversial results about the dynamics of normal NT-proBNP concentrations in infants and children (20, 21, 28, 29), we decided to investigate a distinct age group of infants from 1 month to 3 years of age . Although Mir et al. (20) and Nir et al. (21) found high NT-proBNP concentrations only during the first days of life with no significant differences between healthy children 1 month to 18 years of age, two other studies (28, 29) revealed an age dependency of NT-proBNP concentrations. Recently, the authors of a large study reported a significant impact of age on NT-proBNP measured by the Roche assay, which we used in this study, with values decreasing with increasing age (30), as we found in our study. We excluded infants in the first month of life because this group has very high concentrations of NT-proBNP immediately after birth that subsequently decrease rapidly (21, 28, 29).
Most previous studies investigated the active hormone BNP in children with different heart diseases. BNP concentrations have been shown to increase according to the severity of heart failure symptoms in children (31), and higher BNP concentrations than in controls have been found in pediatric patients with congenital heart diseases that lead to ventricular dysfunction (17, 32) or left or right ventricular volume overload (16,17). However, only a few studies have focused on NT-proBNP in children with cardiac diseases (20-22,33). We found significantly higher NT-proBNP concentrations in young pediatric patients with cardiac diseases compared with controls. In this study, NT-proBNP concentrations (median, 3681 ng/L) in infants with cardiac diseases were not as high as in a recent study involving pediatric patients of the same age (median, 18 452 ng/L) (22). However, the authors of the latter study attempted to differentiate between cardiac and lung diseases in very acutely ill infants with respiratory distress. Thus, the ROC curve analysis revealed unrealistically perfect performance of the marker (AUC 1.0), which clearly needs confirmation. The cutoff value in that study was higher (2940 ng/L) than our cutoff value (2000 ng/L), which is explained by the different study populations. Similar to our study, however, infants with lung diseases did not show significantly different NTproBNP concentrations compared with controls (22). In an earlier study comparing children with and without heart diseases (21), NT-proBNP concentrations (1321 ng/L) were not as high as in our study (3681 ng/L), which may be attributable to the older population studied (4 months-15 years), although no obvious age dependency was found in this previously published study (21). Another study (20) investigating congestive heart failure in patients up to 14 years of age also showed significantly higher NT-proBNP concentrations in children with cardiac diseases than in controls. Because a different assay was used (Biomedica), the absolute concentrations in their cardiac patients exceeded the concentrations in our study and are not easily comparable. When we strictly age- and sex-matched our pediatric heart patients with controls, we still found good and comparable diagnostic performance of NT-proBNP similar to that obtained when we included the whole population, with a similar cutoff value of 2000 ng/L. Recently, NT-proBNP was also found to be a marker of persistent cardiac disease in children (2 days to 14 years of age) with a history of dilated cardiomyopathy or myocarditis (33). Patients with evidence of severe left ventricular dysfunction or dilatation had significantly higher mean NT-proBNP concentrations (3154 ng/L with the Roche assay) than children who had recovered from ventricular dysfunction (122 ng/L) or controls (113 ng/L). Thus, the few currently published studies indicate that the optimal diagnostic cutoff values for cardiac diseases in children seem to depend on the severity of disease, with higher cutoff values in acutely ill pediatric patients, and may also be age dependent, with higher cutoff values in younger infants.
From our results, we conclude, that in a heterogeneous group of young pediatric patients, NT-proBNP showed good diagnostic performance to distinguish between cardiac diseases and various noncardiac diseases. Our ROC analysis suggested a cutoff value of 2000 ng/L for the exclusion of cardiac diseases in children 1 month to 3 years of age if NT-proBNP is measured with the Roche assay.
The NT-proBNP Elecsys assays were gifts from Roche (Vienna, Austria). The assay manufacturer had no influence on study design, data analysis or interpretation, or the content of this manuscript.
(1.) Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
(2.) Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
(3.) Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347: 161-7.
(4.) Hammerer-Lercher A, Ludwig W, Falkensammer G, Muller S, Neubauer E, Puschendorf B, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performances of markers. Clin Chem 2004;50:1174-83.
(5.) Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal probrain natriuretic peptide, brain natriuretic peptide and, N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7.
(6.) Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8:149-54.
(7.) Nagaya N, Goto Y, Nishikimi T, Uematsu M, Miyao Y, Kobayashi Y, et al. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. Clin Sci 1999;96:129-36.
(8.) Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-Type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107: 2786-92.
(9.) de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
(10.) Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.
(11.) Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-Terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
(12.) Kragelund C, Kistorp C, Pedersen F, Raymond I, Hildebrandt P. Biochemical cardiac risk markers in the general population, hypertension, and coronary artery disease. Scand J Clin Lab Invest Suppl 2005;240:138-42.
(13.) Anand IS, Fisher LID, Chiang YT, Latini R, Masson S, Maggioni AP, et al.; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107: 1278-83.
(14.) Hoch M, Netz H. Heart failure in pediatric patients. Thorac Cardiovasc Surg 2005;2:S129-S134.
(15.) Nir A, Nasser N. Clinical value of NT-proBNP and BNP in pediatric cardiology. J Card Fail 2005;11:S76-80.
(16.) Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003;57:191-7.
(17.) Westerlind A, Wahlander H, Lindstedt G, Lundberg P-A, Holmgren D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004; 93:340-5.
(18.) Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-54.
(19.) Cowley CG, Bradley JD, Shaddy RE. B-Type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004;5:336-40.
(20.) Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:e76.
(21.) Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-Terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence: elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004;93:603-7.
(22.) Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics 2005;115: 1347-50.
(23.) Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004;25:341-6.
(24.) Connolly D, Rutkowski M, Auslender M, Artman M. The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J Pediatr 2001;138: 644-8.
(25.) Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest 1999;59:177-81.
(26.) Collinson P0, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365-8.
(27.) Zweig MH, Campell G. Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
(28.) Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005;94:399-404.
(29.) Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003;49:1563-4.
(30.) Albers S, Mir TS, Haddad M, Laer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 2006;44:80-5.
(31.) Ohuchi H, Takasugi H, Ohashi H, Okada Y, Yamada 0, Ono Y, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003;108:2368-76.
(32.) Law YM, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 2005;95:474-8.
(33.) Nasser N, Perles Z, Rein AJ, Nir A. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2005;27:87-90.
ANGELIKA HAMMERER-LERCHER, * RALF GEIGER,  JOHANNES MAIR,  CHRISTOPH URL,  GERALD TULZER,  EVELYN LECHNER,  BERND PUSCHENDORF,  and RUDOLF SOMMER 
 Division of Clinical Biochemistry, Innsbruck Biocenter, and  Departments of Pediatrics, Clinical Division of Pediatric Cardiology, and  Internal Medicine, Clinical Division of Cardiology, Innsbruck Medical University, Austria.
 Department of Pediatric Cardiology, Pediatric Center, Linz, Austria.
 Department of Clinical Laboratory and Blood Depot, Gynaecologic and Pediatric District Hospital, Linz, Austria.
 Nonstandard abbreviations: BNP, B-type natriuretic peptide; NTproBNP, N-terminal pro-B-type natriuretic peptide; NYU PHFI, New York University Pediatric Heart Failure Index; CI, confidence interval; and AUC, area under the curve.
* Address correspondence to this author at: Division of Clinical Biochemistry, Innsbruck Biocenter, Medical University, Fritz-Pregl-Strasse 3, A-6020 Innsbruck, Austria. Fax 43-512-507-2876; e-mail Angelika.Lercher@uibk.ac.at.
Received September 14, 2005; accepted April 18, 2006.
Previously published online at DOI: 10.1373/clinchem.2005.060608
Table 1. NT-proBNP concentrations in infants with cardiac or noncardiac diseases. No. of NT-proBNP, Disease infants (a) ng/L Cardiac diseases 23 3681 (1045-13 557) Noncardiac diseases 119 241 (116-542) (b) Noncardiac disease subgroups Kidney 7 317 (215-379) (c) Lung 15 174 (102-1262) (b) Central nervous system 9 247 (72-640) (d) Other 88 226 (116-439) (b) (a) Median (25th-75th percentiles). (b-d) Compared with patients with cardiac diseases: (b) P < 0.0001; (c) P = 0.005; (d) P = 0.001.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Pediatric Clinical Chemistry|
|Author:||Hammerer-Lercher, Angelika; Geiger, Ralf; Mair, Johannes; Url, Christoph; Tulzer, Gerald; Lechner, E|
|Article Type:||Clinical report|
|Date:||Jul 1, 2006|
|Previous Article:||Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress.|
|Next Article:||Integrated single-label liquid-phase assay of APOE codons 112 and 158 and a lipoprotein study in British women.|